
Pipeline
Aldeyra is dedicated to improving the lives of patients suffering from immune-mediated ocular and systemic diseases. We are advancing a broad pipeline of product candidates diversified by chemical composition, mechanism of action, and clinical indication.
Our clinical pipeline encompasses three distinct biological mechanisms of action: Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase (DHFR) inhibition, and Chaperome (CHP) inhibition. The immunological activity of our product candidates may potentially lead to diminished levels of pathological inflammation via the down-regulation of immune cell activation or proliferation.